We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.105 | 2.26% | 4.755 | 4.52 | 4.99 | - | 189,060 | 16:35:30 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.53 | 9.36M |
Date | Subject | Author | Discuss |
---|---|---|---|
13/8/2020 13:45 | yet another final - thanks for posting. Do you know who produced that peer summary? | dibs61 | |
13/8/2020 12:38 | Just a quote from one of the peers re results:This is a phase 2 study where limited numbers of patients are enrolled in order to quickly acquire enough data to analyse whether the drug has beneficial effects. In such studies, one usually looks across the whole range of results, rather than putting excessive focus on the primary endpoint; this allows us to understand whether the effects are consistent or could be spurious false positive artefacts due to a small sample size. It is extremely encouraging to see positive results across different endpoints, and in the subgroup of more severely affected individuals who needed oxygen at the time of hospital admission. The most important result appears to be a reduction in the number of patients requiring ventilation. While some caution should be applied until we see the full publication of data, these results suggest that interferon beta urgently warrants further evaluation as a treatment for COVID-19.So positive results ACROSS the different endpoints.... Very heartening | yet another final | |
13/8/2020 12:30 | Still looks like there's a buy order in the market...... just an observation!! | nortic 007 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions